
MDAI Stock Forecast & Price Target
MDAI Analyst Ratings
Bulls say
Spectral AI is expected to experience significant growth in the coming years as it receives FDA clearance and begins its commercial launch of the DeepView System in the second half of 2026, with BARDA's support in distributing systems to burn centers and emergency departments in the US. The company's license model and focus on the underpenetrated and disjointed Advanced Wound Care market provide opportunities for recurring revenue and potential for Democratization of treatment. However, there are potential risks such as setbacks in regulatory or commercial approvals and lower uptake of the DeepView system in a commercial setting. The company's valuation and potential for revenue growth makes it a Buy with a PT of $4.00 based on a discounted sales analysis out to 2030.
Bears say
Spectral AI is a recent addition to the public market, with its DeepView system offering a potential solution for the under-penetrated and disjointed advanced wound care market. However, despite a recent BARDA contract and plans for international expansion, the company has yet to generate significant revenue and faces potential risks such as limited awareness of the technology and delays in regulatory and clinical timelines. Investors should approach this stock with caution and closely monitor its progress.
This aggregate rating is based on analysts' research of Spectral AI Inc and is not a guaranteed prediction by Public.com or investment advice.
MDAI Analyst Forecast & Price Prediction
Start investing in MDAI
Order type
Buy in
Order amount
Est. shares
0 shares